Long-term vs. Short-term Androgen Deprivation Combined with High-dose Radiotherapy for Intermediate and High-risk Prostate Cancer: Preliminary Results of a GICOR Phase III Randomized Trial

      Although androgen deprivation (AD) combined with radiotherapy significantly decreases recurrences and mortality of patients affected by locally advanced prostate cancer (PCa), controversy remains about the optimal duration of AD when associated to high-dose radiotherapy (HDRT). This trial was designed to determine whether long-term AD (LTAD) is superior to short-term AD (STAD) in the setting of HDRT.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.